AI Integration for Clinical Trial Site Selection and Feasibility

The integration connects to your existing Clinical Trial Management System (CTMS)—such as Veeva Vault CTMS, Oracle Clinical One, or Medidata Rave—and external patient population databases (e.g., TriNetX, Flatiron) via APIs. AI agents ingest historical site performance data, protocol requirements, and real-world evidence to score and rank potential sites. Key CTMS objects like Site, Investigator, Study, and Feasibility Questionnaire become primary data sources, while the AI's output—a ranked site list with confidence scores and rationale—is written back to a custom object or attached to the study record for team review.

A practical workflow begins when a new protocol is loaded into the CTMS. An AI agent is triggered via webhook to analyze the protocol's inclusion/exclusion criteria against geospatial demographic data, historical enrollment rates from similar studies, and site regulatory inspection histories. It then generates a feasibility report that predicts enrollment timelines, identifies potential bottlenecks (e.g., competing trials, staffing shortages), and recommends a shortlist of high-probability sites. This shifts site identification from a manual spreadsheet exercise taking weeks to an automated analysis completed in hours, allowing clinical operations to focus on relationship-building and activation.

Rollout is typically phased, starting with a pilot study to validate the AI's recommendations against traditional selection methods. Governance is critical: a human-in-the-loop approval step is maintained within the CTMS workflow where the study team reviews and adjusts the AI's rankings. All recommendations, data sources, and user overrides are logged to an audit trail for compliance and model refinement. This approach de-risks implementation, ensures regulatory alignment, and builds trust by augmenting—not replacing—clinical expertise.

For production, the AI layer is deployed as a containerized service that calls the CTMS REST API for data and posts results back. It requires a vector database (like Pinecone or Weaviate) to store and semantically search historical trial documents and site profiles. The final architecture reduces site selection cycle time, improves enrollment forecast accuracy by 20-30%, and provides a data-driven rationale for monitoring resource allocation, directly impacting study timelines and cost.

The core architecture establishes a bi-directional data pipeline between your Clinical Trial Management System (e.g., Veeva Vault CTMS, Oracle Clinical One) and the AI engine. Key data objects are extracted via platform APIs or from a clinical data warehouse: historical protocol documents, site performance metrics (enrollment rates, query volume, monitoring findings), country/site regulatory profiles, and patient population databases. This raw data is normalized, with sensitive information pseudonymized, before being ingested into a vector store for semantic search and a structured database for model training and scoring.

The AI workflow is triggered by a new protocol draft or a study startup request within the CTMS. An agent orchestrates the analysis: a retrieval-augmented generation (RAG) system queries the vector store for similar historical protocols and site outcomes, while a predictive model scores candidate sites based on feasibility criteria. The output is a ranked site list with confidence scores and rationale, delivered as a structured payload back to the CTMS. This can create a new "AI Feasibility Assessment" record linked to the study, or populate custom objects for review by clinical operations leaders. The system boundary is maintained—the CTMS remains the system of record, while the AI acts as a decision-support service.

Governance and rollout require a phased approach. Start with a read-only, human-in-the-loop pilot: scores are presented in a dedicated dashboard or CTMS report for manual validation by feasibility managers. Prompts, models, and data sources are version-controlled in an LLMOps platform. As confidence grows, workflows can be automated, such as auto-populating site identification lists or triggering alerts when a high-scoring site declines. Audit trails log every data input, model version, and score generated, ensuring reproducibility for quality audits. This architecture turns months of manual feasibility analysis into a repeatable, data-driven process that scales with your trial portfolio.

An AI integration for clinical trial site feasibility must be built with a governance-first architecture. This means all AI-generated scores, recommendations, and data analyses are logged as discrete records within your CTMS (e.g., Veeva Vault CTMS or Oracle Clinical One) or a dedicated audit database. Each recommendation should be traceable to its source data—historical site performance metrics, patient population database queries, and regulatory intelligence—and include the model version, prompt, and confidence score. This creates a clear audit trail for protocol amendments, regulatory inquiries, and internal quality reviews.

A phased rollout is critical for adoption and risk management. Start with a pilot phase focused on augmenting, not replacing, manual feasibility reviews. Integrate the AI to analyze a subset of historical studies and new protocol drafts, generating site scorecards that are presented alongside traditional reports in a CTMS dashboard or a dedicated portal. This allows feasibility teams to compare AI insights with their own expertise, building trust and identifying edge cases. Subsequent phases can introduce automated alerting for high-potential sites or regulatory risks directly into study startup workflows within the CTMS, triggering tasks for site identification managers.

Compliance is enforced through human-in-the-loop approvals and role-based access control (RBAC). For instance, a system can be configured so that any AI-recommended site added to a study's official feasibility shortlist requires a documented review and electronic sign-off from the assigned Feasibility Lead within the CTMS. Access to raw model outputs and configuration settings should be restricted to authorized AI stewards and IT administrators, while study teams interact with curated, explainable insights. This controlled, phased approach de-risks the integration, aligns with ICH GCP principles of data integrity, and delivers incremental value, moving from an assistive tool to a core component of the strategic planning workflow.